Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLRBNASDAQ:INABNASDAQ:UBXNASDAQ:ZVSA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLRBCellectar Biosciences$0.36-11.6%$0.27$0.22▼$3.42$16.63M0.483.84 million shs8.88 million shsINABIN8bio$4.17+15.7%$0.15$0.68▼$52.20$378.52M0.1884,525 shs517,414 shsUBXUnity Biotechnology$0.68-1.0%$0.89$0.66▼$3.10$11.72M1.28130,104 shs153,202 shsZVSAZyVersa Therapeutics$0.65+1.5%$0.67$0.47▼$6.30$3.13M0.741.48 million shs324,489 shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLRBCellectar Biosciences-11.61%+54.58%+67.94%+28.33%-86.88%INABIN8bio-1.96%-21.71%-27.21%-51.36%-91.23%UBXUnity Biotechnology-4.76%+1.18%-25.22%-59.05%-57.00%ZVSAZyVersa Therapeutics+3.96%-2.08%+17.05%-34.16%-86.83%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCLRBCellectar Biosciences1.2666 of 5 stars3.22.00.00.01.10.00.6INABIN8bio2.4467 of 5 stars3.53.00.00.01.12.50.6UBXUnity Biotechnology4.3435 of 5 stars3.34.00.04.72.70.81.3ZVSAZyVersa Therapeutics0.5885 of 5 stars0.05.00.00.00.80.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLRBCellectar Biosciences 2.33Hold$12.503,364.52% UpsideINABIN8bio 3.00Buy$6.0043.88% UpsideUBXUnity Biotechnology 2.50Moderate Buy$3.75450.66% UpsideZVSAZyVersa Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ZVSA, INAB, CLRB, and UBX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/27/2025UBXUnity BiotechnologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$4.00 ➝ $2.005/16/2025UBXUnity BiotechnologyMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Neutral$6.00 ➝ $1.005/14/2025CLRBCellectar BiosciencesMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold4/23/2025UBXUnity BiotechnologyChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.004/23/2025UBXUnity BiotechnologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.003/25/2025UBXUnity BiotechnologyChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$6.00 ➝ $4.003/24/2025UBXUnity BiotechnologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$8.00 ➝ $4.003/14/2025INABIN8bioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$8.00 ➝ $6.003/10/2025UBXUnity BiotechnologyChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.003/10/2025UBXUnity BiotechnologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.00(Data available from 6/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLRBCellectar BiosciencesN/AN/AN/AN/A($0.96) per shareN/AINABIN8bioN/AN/AN/AN/A$0.58 per shareN/AUBXUnity Biotechnology$240K48.84N/AN/A$1.69 per share0.40ZVSAZyVersa TherapeuticsN/AN/AN/AN/A$88.98 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLRBCellectar Biosciences-$42.77M-$0.73N/AN/AN/AN/AN/A-191.22%8/13/2025 (Estimated)INABIN8bio-$30.01M-$0.45N/AN/AN/AN/A-197.15%-130.48%8/14/2025 (Estimated)UBXUnity Biotechnology-$39.86M-$1.62N/AN/AN/AN/A-119.70%-45.86%7/22/2025 (Estimated)ZVSAZyVersa Therapeutics-$98.30MN/A0.00N/AN/AN/A-224.85%-103.22%8/14/2025 (Estimated)Latest ZVSA, INAB, CLRB, and UBX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025CLRBCellectar Biosciences-$0.17-$0.13+$0.04-$0.14N/AN/A5/12/2025Q1 2025ZVSAZyVersa Therapeutics-$0.40-$0.73-$0.33-$0.73N/AN/A5/8/2025Q1 2025INABIN8bio-$0.06-$0.07-$0.01-$0.07N/AN/A4/22/2025Q1 2025UBXUnity Biotechnology-$0.43-$0.43N/A-$0.43N/AN/A3/13/2025Q4 2024INABIN8bio-$0.07-$0.04+$0.03-$0.04N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLRBCellectar BiosciencesN/AN/AN/AN/AN/AINABIN8bioN/AN/AN/AN/AN/AUBXUnity BiotechnologyN/AN/AN/AN/AN/AZVSAZyVersa TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLRBCellectar BiosciencesN/A1.771.77INABIN8bio0.051.841.84UBXUnity BiotechnologyN/A3.453.45ZVSAZyVersa TherapeuticsN/A0.030.03Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLRBCellectar Biosciences16.41%INABIN8bio92.05%UBXUnity Biotechnology29.49%ZVSAZyVersa Therapeutics3.91%Insider OwnershipCompanyInsider OwnershipCLRBCellectar Biosciences3.70%INABIN8bio15.50%UBXUnity Biotechnology5.80%ZVSAZyVersa Therapeutics0.21%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLRBCellectar Biosciences1046.08 million44.38 millionOptionableINABIN8bio2090.77 million61.25 millionNot OptionableUBXUnity Biotechnology6017.21 million15.87 millionOptionableZVSAZyVersa Therapeutics24.77 million2.34 millionNot OptionableZVSA, INAB, CLRB, and UBX HeadlinesRecent News About These CompaniesZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) Sees Large Drop in Short InterestMay 31, 2025 | americanbankingnews.comZyVersa Therapeutics Highlights Published Study Reinforcing That Microglia-driven Inflammation Is Pivotal in Development of Parkinson’s and Alzheimer’s DiseasesMay 22, 2025 | seekingalpha.comZyVersa Therapeutics Highlights New Research Supporting Inflammasome ASC Inhibitor IC 100 as Potential Treatment for Parkinson's DiseaseMay 20, 2025 | quiverquant.comZyVersa Therapeutics Highlights Published Study Reinforcing That Microglia-driven Inflammation Is Pivotal in Development of Parkinson's and Alzheimer's DiseasesMay 20, 2025 | globenewswire.comZyVersa Therapeutics, Inc. Provides Pipeline and Financial Update: Advances in Clinical Trials for VAR 200 and IC 100May 14, 2025 | nasdaq.comZyVersa Therapeutics Reports First Quarter 2025 Financial Results and Highlights Pipeline ProgressMay 12, 2025 | globenewswire.comZyVersa progresses with obesity inflammation treatmentMay 9, 2025 | uk.investing.comZyVersa Unveils Groundbreaking Potential of Inflammasome Inhibitors in Combination with GLP-1 Agonists to Address Unmet Medical Needs of People Living with Obesity; Provides R&D UpdateMay 7, 2025 | globenewswire.comZyVersa Therapeutics Announces Published Data Showing Inflammasome ASC Inhibitor IC 100 Decreases Microglial Inflammasome Activation and Alpha-Synuclein That Contribute to ...April 29, 2025 | msn.comZyVersa Therapeutics Announces Published Data Showing Inflammasome ASC Inhibitor IC 100 Decreases Microglial Inflammasome Activation and Alpha-Synuclein That Contribute to Neurodegeneration in Parkinson's DiseaseApril 29, 2025 | globenewswire.comZyVersa Therapeutics CEO provides update on inflammasome ASC inhibitor IC 100April 25, 2025 | markets.businessinsider.comZyVersa Therapeutics CEO Issues Shareholder Letter Announcing Transformative R&D Trends for Inflammasome Inhibitors, and Provides Update on Inflammasome ASC Inhibitor IC 100's Development StatusApril 24, 2025 | globenewswire.comZyVersa Therapeutics CEO Issues Shareholder Letter on PARASOL Recommendations Expected to Reduce Drug Development Barrier for Rare Kidney Disease, Focal Segmental ...April 10, 2025 | seekingalpha.comWhy ZyVersa Therapeutics, Inc. (ZVSA) Went Down On Thursday?April 10, 2025 | msn.comWhy ZyVersa Therapeutics, Inc. (ZVSA) Went Down On Thursday?April 10, 2025 | insidermonkey.comZyVersa Therapeutics CEO Issues Shareholder Letter on PARASOL Recommendations Expected to Reduce Drug Development Barrier for Rare Kidney Disease, Focal Segmental Glomerulosclerosis (FSGS)April 8, 2025 | globenewswire.comZyVersa Therapeutics files to sell 4.21M shares of common stock for holdersApril 5, 2025 | markets.businessinsider.comZyVersa Therapeutics reports FY24 EPS ($8.48) vs. ($1089.70) last yearMarch 28, 2025 | markets.businessinsider.comZyVersa Therapeutics expects cash to fund requirements on month-to-month basisMarch 28, 2025 | markets.businessinsider.comZyVersa Therapeutics Reports Full Year 2024 Financial Results and Provides Business UpdateMarch 27, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsPfizer's 7.5% Dividend: Income Haven or House of Cards?By Jeffrey Neal Johnson | May 23, 2025View Pfizer's 7.5% Dividend: Income Haven or House of Cards?3 Underrated Stocks Quietly Delivering Big GainsBy Thomas Hughes | May 13, 2025View 3 Underrated Stocks Quietly Delivering Big GainsRed Robin's Comeback: Q1 Earnings Spark Investor HopesBy Jeffrey Neal Johnson | June 5, 2025View Red Robin's Comeback: Q1 Earnings Spark Investor HopesZVSA, INAB, CLRB, and UBX Company DescriptionsCellectar Biosciences NASDAQ:CLRB$0.36 -0.05 (-11.59%) Closing price 04:00 PM EasternExtended Trading$0.35 -0.01 (-2.72%) As of 05:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.IN8bio NASDAQ:INAB$4.17 +0.57 (+15.74%) Closing price 04:00 PM EasternExtended Trading$3.70 -0.47 (-11.27%) As of 05:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM. It also develops INB-300, INB-410, and INB-500 that are in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.Unity Biotechnology NASDAQ:UBX$0.68 -0.01 (-1.02%) Closing price 04:00 PM EasternExtended Trading$0.72 +0.04 (+5.73%) As of 05:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2048, a Tie2/VEGF bispecific; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.ZyVersa Therapeutics NASDAQ:ZVSA$0.65 +0.01 (+1.50%) Closing price 04:00 PM EasternExtended Trading$0.65 0.00 (-0.60%) As of 05:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity. ZyVersa Therapeutics, Inc. was founded in 2014 and is headquartered in Weston, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas This Banking Giant Just Got a $90 Price Target Upgrade Broadcom Slides on Solid Earnings, AI Outlook Still Strong The Market’s Silent Warning: What Bonds and Gold Reveal MongoDB Affirms Outlook and Accelerates Stock Price Reversal Are NVIDIA's Ethernet Wins Signs of Hope or Horror for Arista? AT&T: Is This Telecom Giant a Buy or a Bye for Your Portfolio? Why Visa's Innovation Engine Keeps It a Top Portfolio Pick Is Meta Plotting a Stablecoin Comeback Years After Libra's Flop? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
